Morgan Stanley
BDTX icon

Morgan Stanley’s Black Diamond Therapeutics BDTX Stock Holding History

Morgan Stanley’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$428K Buy
231,200
+142,577
+161% +$349K ﹤0.01% 5620
2026
Q1 		$189K Sell
88,623
-6,526
-7% -$15.5K ﹤0.01% 5901
2025
Q4 		$231K Buy
95,149
+26,011
+38% +$92.1K ﹤0.01% 5876
2025
Q3 		$262K Sell
69,138
-21,180
-23% -$62K ﹤0.01% 5783
2025
Q2 		$224K Sell
90,318
-334,042
-79% -$644K ﹤0.01% 5805
2025
Q1 		$658K Buy
424,360
+206,340
+95% +$433K ﹤0.01% 5206
2024
Q4 		$467K Buy
218,020
+93,016
+74% +$267K ﹤0.01% 5442
2024
Q3 		$544K Sell
125,004
-91,324
-42% -$497K ﹤0.01% 5364
2024
Q2 		$1.01M Buy
216,328
+157,430
+267% +$845K ﹤0.01% 4956
2024
Q1 		$299K Buy
58,898
+47,067
+398% +$190K ﹤0.01% 5563
2023
Q4 		$33.2K Sell
11,831
-10,220
-46% -$24K ﹤0.01% 6295
2023
Q3 		$63.3K Buy
22,051
+5,782
+36% +$21.3K ﹤0.01% 6066
2023
Q2 		$82.2K Sell
16,269
-11,705
-42% -$23.9K ﹤0.01% 6029
2023
Q1 		$52.9K Sell
27,974
-3,228
-10% -$7.42K ﹤0.01% 6269
2022
Q4 		$56.2K Sell
31,202
-197,987
-86% -$357K ﹤0.01% 6240
2022
Q3 		$387K Sell
229,189
-307,031
-57% -$947K ﹤0.01% 5392
2022
Q2 		$1.32M Buy
536,220
+42,858
+9% +$99.6K ﹤0.01% 4832
2022
Q1 		$1.37M Sell
493,362
-280,574
-36% -$1.02M ﹤0.01% 4780
2021
Q4 		$4.13M Buy
773,936
+12,845
+2% +$89.7K ﹤0.01% 3917
2021
Q3 		$6.44M Buy
761,091
+160,071
+27% +$1.58M ﹤0.01% 3412
2021
Q2 		$7.33M Buy
601,020
+588,232
+4,600% +$11.6M ﹤0.01% 3361
2021
Q1 		$311K Sell
12,788
-98,873
-89% -$2.67M ﹤0.01% 5400
2020
Q4 		$3.58M Buy
111,661
+103,150
+1,212% +$3.39M ﹤0.01% 3622
2020
Q3 		$257K Buy
8,511
+4,695
+123% +$143K ﹤0.01% 4974
2020
Q2 		$161K Buy
3,816
+2,406
+171% +$88.6K ﹤0.01% 5179
2020
Q1 		$35K Buy
+1,410
New +$42.9K ﹤0.01% 5588

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Morgan Stanley's BDTX Position: Q2 2026 in Review

Morgan Stanley increased its Black Diamond Therapeutics (BDTX) stake by 161% in Q2 2026, buying an estimated $349K and bringing the position to 231,200 shares worth $428K. The position accounts for ﹤0.01% of the portfolio, ranked #5620.

Morgan Stanley first reported a position in BDTX in Q1 2020 and has held it in 26 quarters since. The position peaked at $7.33M in Q2 2021. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Morgan Stanley held 231,200 shares of Black Diamond Therapeutics worth $428K as of Q2 2026.
  • Morgan Stanley bought 142,577 Black Diamond Therapeutics shares in Q2 2026, an estimated $349K.
  • Black Diamond Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5620 holding.
  • Morgan Stanley first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Morgan Stanley's Black Diamond Therapeutics position peaked at $7.33M in Q2 2021.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.